IL255898A - Converted pyrazole and pyrrole compounds and methods of using them to prevent the onset of conversion and treat related diseases - Google Patents
Converted pyrazole and pyrrole compounds and methods of using them to prevent the onset of conversion and treat related diseasesInfo
- Publication number
- IL255898A IL255898A IL255898A IL25589817A IL255898A IL 255898 A IL255898 A IL 255898A IL 255898 A IL255898 A IL 255898A IL 25589817 A IL25589817 A IL 25589817A IL 255898 A IL255898 A IL 255898A
- Authority
- IL
- Israel
- Prior art keywords
- initiation
- inhibition
- translation
- diseases
- treatment
- Prior art date
Links
- NOIXNOMHHWGUTG-UHFFFAOYSA-N 2-[[4-[4-pyridin-4-yl-1-(2,2,2-trifluoroethyl)pyrazol-3-yl]phenoxy]methyl]quinoline Chemical compound C=1C=C(OCC=2N=C3C=CC=CC3=CC=2)C=CC=1C1=NN(CC(F)(F)F)C=C1C1=CC=NC=C1 NOIXNOMHHWGUTG-UHFFFAOYSA-N 0.000 title 1
- 208000037765 diseases and disorders Diseases 0.000 title 1
- 230000005764 inhibitory process Effects 0.000 title 1
- 230000000977 initiatory effect Effects 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 150000003233 pyrroles Chemical class 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562169376P | 2015-06-01 | 2015-06-01 | |
| PCT/US2016/035288 WO2016196644A1 (en) | 2015-06-01 | 2016-06-01 | Substituted pyrazole and pyrrole compounds and methods for using them for inhibition of initiation of translation and treatment of diseases and disorders relating thereto |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL255898A true IL255898A (en) | 2018-01-31 |
Family
ID=56118071
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL255898A IL255898A (en) | 2015-06-01 | 2017-11-26 | Converted pyrazole and pyrrole compounds and methods of using them to prevent the onset of conversion and treat related diseases |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US10537558B2 (enExample) |
| EP (1) | EP3303332A1 (enExample) |
| JP (1) | JP6707630B2 (enExample) |
| CN (1) | CN108349962A (enExample) |
| BR (1) | BR112017025851A2 (enExample) |
| CA (1) | CA3025492A1 (enExample) |
| IL (1) | IL255898A (enExample) |
| MX (1) | MX2017015456A (enExample) |
| WO (1) | WO2016196644A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10537558B2 (en) | 2015-06-01 | 2020-01-21 | Bantam Pharmaceutical, Llc | Substituted pyrazole and pyrrole compounds and methods for using them for inhibition of initiation of translation and treatment of diseases and disorders relating thereto |
| MX2019006296A (es) * | 2016-11-30 | 2019-11-12 | Bantam Pharmaceutical Llc | Métodos de uso de compuestos de pirazol y pirazol sustituido y para el tratamiento de enfermedades hiperproliferativas. |
| AU2017366901B2 (en) | 2016-11-30 | 2022-09-29 | Bantam Pharmaceutical, Llc | Substituted pyrazole compounds and methods of using them for treatment of hyperproliferative diseases |
| US11779018B2 (en) | 2018-03-30 | 2023-10-10 | Sumitomo Chemical Company, Limited | Heterocyclic compound and arthropod pest control composition containing same |
| CN112770813A (zh) * | 2018-06-07 | 2021-05-07 | 班塔姆制药有限责任公司 | 用经取代的吡咯和吡唑化合物治疗癌症及诊断对用经取代的吡咯和吡唑化合物的治疗敏感的癌症的方法 |
| US12030875B2 (en) | 2018-09-07 | 2024-07-09 | PIC Therapeutics, Inc. | EIF4E inhibitors and uses thereof |
| CN110950848B (zh) * | 2018-09-27 | 2024-03-26 | 徐诺药业 | 新型氨基吡唑类衍生物的合成与应用 |
| EP3976605B1 (en) * | 2019-05-31 | 2025-08-20 | Bantam Pharmaceutical, LLC | Methods for making thiazolylpyrazole carboxylic acids and intermediates therefor |
| EP4053123A4 (en) | 2019-11-01 | 2023-10-11 | Unimatec Co., Ltd. | FLUORINATED PYRIMIDINE COMPOUND AND METHOD FOR THE PRODUCTION THEREOF |
| CA3170411A1 (en) | 2020-03-03 | 2021-09-10 | Christopher L. Vandeusen | Eif4e inhibitors and uses thereof |
| CN118019739A (zh) | 2021-08-25 | 2024-05-10 | 皮克医疗公司 | Eif4e抑制剂及其用途 |
| US12234231B2 (en) | 2021-08-25 | 2025-02-25 | PIC Therapeutics, Inc. | EIF4E inhibitors and uses thereof |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5342851A (en) * | 1992-10-07 | 1994-08-30 | Mcneil-Ppc, Inc. | Substituted thiazole derivatives useful as platelet aggregation inhibitors |
| IT1301968B1 (it) * | 1998-07-30 | 2000-07-20 | Zambon Spa | Derivati di eritromicina ad attivita' antibiotica |
| DK1104759T3 (da) * | 1999-12-03 | 2004-01-26 | Pfizer Prod Inc | Heteroarylphenylpyrazolforbindelser som antiinflammatoriske/analgetiske midler |
| EP1513534A2 (en) * | 2002-04-04 | 2005-03-16 | Cv Therapeutics, Inc. | Compounds for increasing abca-1 expression useful for treating coronary artery disease and atherosclerosis |
| US20060194807A1 (en) | 2003-04-03 | 2006-08-31 | Cosford Nicholas D P | Di-aryl substituted pyrazole modulators of metabotropic glutamate receptor-5 |
| WO2004094395A2 (en) | 2003-04-18 | 2004-11-04 | Merck & Co., Inc. | Biaryl substituted thiazoles, oxazoles and imidazoles as sodium channel blockers |
| WO2007138110A2 (en) | 2006-06-01 | 2007-12-06 | Devgen N.V. | Compounds that interact with ion channels, in particular with ion channels from the kv family |
| WO2008121861A2 (en) | 2007-03-28 | 2008-10-09 | Xenon Pharmaceuticals Inc. | Pyrazole and pyrrole compounds useful in treating iron disorders |
| KR20100065340A (ko) * | 2007-08-27 | 2010-06-16 | 바스프 에스이 | 무척추 해충을 방제하기 위한 피라졸 화합물 |
| US8461348B2 (en) | 2008-04-04 | 2013-06-11 | Takeda Pharmaceutical Company Limited | Heterocyclic derivative and use thereof |
| PT2275414E (pt) | 2008-04-28 | 2015-09-09 | Teijin Pharma Ltd | Derivado de amida do ácido ciclopentacrílico |
| AU2011343039B2 (en) * | 2010-12-14 | 2017-03-02 | Electrophoretics Limited | Casein kinase 1delta (CK1delta) inhibitors |
| JP2015534990A (ja) * | 2012-10-22 | 2015-12-07 | イージェニックス インコーポレイテッド | 誤制御されたｅＩＦ４Ｅに関連する疾患又は障害を治療又は予防するための組成物及び方法 |
| CA2943659C (en) | 2014-03-27 | 2023-04-25 | Merck Patent Gmbh | Pyridyl piperidines |
| US10125139B2 (en) | 2015-04-24 | 2018-11-13 | Syngenta Crop Protection Ag | Pesticidally active polycyclic derivatives with sulfur substituted five-membered ring heterocycles |
| US10537558B2 (en) | 2015-06-01 | 2020-01-21 | Bantam Pharmaceutical, Llc | Substituted pyrazole and pyrrole compounds and methods for using them for inhibition of initiation of translation and treatment of diseases and disorders relating thereto |
-
2016
- 2016-06-01 US US15/578,585 patent/US10537558B2/en active Active
- 2016-06-01 JP JP2018515175A patent/JP6707630B2/ja not_active Expired - Fee Related
- 2016-06-01 BR BR112017025851-0A patent/BR112017025851A2/pt not_active Application Discontinuation
- 2016-06-01 WO PCT/US2016/035288 patent/WO2016196644A1/en not_active Ceased
- 2016-06-01 CN CN201680045318.9A patent/CN108349962A/zh active Pending
- 2016-06-01 MX MX2017015456A patent/MX2017015456A/es unknown
- 2016-06-01 EP EP16728546.9A patent/EP3303332A1/en not_active Withdrawn
- 2016-06-01 CA CA3025492A patent/CA3025492A1/en not_active Abandoned
-
2017
- 2017-11-26 IL IL255898A patent/IL255898A/en unknown
-
2020
- 2020-01-21 US US16/748,429 patent/US11602526B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP3303332A1 (en) | 2018-04-11 |
| US20180311218A1 (en) | 2018-11-01 |
| JP6707630B2 (ja) | 2020-06-10 |
| US20200261424A1 (en) | 2020-08-20 |
| BR112017025851A2 (pt) | 2018-10-16 |
| CA3025492A1 (en) | 2016-12-08 |
| CN108349962A (zh) | 2018-07-31 |
| US11602526B2 (en) | 2023-03-14 |
| WO2016196644A1 (en) | 2016-12-08 |
| US10537558B2 (en) | 2020-01-21 |
| JP2018521119A (ja) | 2018-08-02 |
| MX2017015456A (es) | 2018-11-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL255898A (en) | Converted pyrazole and pyrrole compounds and methods of using them to prevent the onset of conversion and treat related diseases | |
| IL266930A (en) | Modified pyrazole compounds and methods of using them for the treatment of hyperproliferative diseases | |
| IL266931A (en) | Methods of using modified pyrazole and pyrazole compounds for the treatment of hyperproliferative diseases | |
| SI4122464T1 (sl) | Terapevtske kombinacije za zdravljenje bolezni jeter | |
| IL269302A (en) | Pyrimidinyl-pyridyloxy-naphthyl compounds and methods of treating ire1-related diseases and disorders | |
| ZA201807084B (en) | Methods of treatment of cholestatic diseases | |
| EP3668993A4 (en) | HEPATIC DISEASE TREATMENT METHODS | |
| IL253945A0 (en) | kdm1a inhibitors to treat the disease | |
| IL275321A (en) | Treatment of diseases associated with the expression of DUX4 | |
| IL259281B (en) | History of bipyrazolyl used in the treatment of autoimmune diseases | |
| IL254568A0 (en) | Compounds and forms for the treatment of female sexual disorders | |
| ZA201906213B (en) | Compounds and methods for the treatment of parasitic diseases | |
| IL320533A (en) | Methods and compositions for treating disorders and diseases involving RDH12 | |
| IL261277A (en) | Combination therapies for treatment of spinal muscular atrophy | |
| EP3340974A4 (en) | METHODS OF TREATING DISEASES | |
| ZA201705877B (en) | Method of treating diseases | |
| PL3500586T3 (pl) | Sposób ciągły zmniejszania heterogeniczności białka terapeutycznego | |
| IL279497A (en) | Treatment of protein in the urine | |
| GB201612043D0 (en) | Composition for treatment of disorders | |
| IL253847A0 (en) | Methods of treating diseases | |
| EP3251699A4 (en) | Composition and method for treatment of neuropsychiatric disorders | |
| SG11201705889VA (en) | Prevention or Treatment of Uratic or Gouty Diseases | |
| ZA202001927B (en) | Method for treating tnf alpha-related diseases | |
| IL252543B (en) | Compounds for the treatment of degenerative retinal tissues | |
| IL265596A (en) | Methods for treating ocular disease using inhibitors of csf-1r |